Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Aristo Bio-Tech and Lifescience's Debt-to-EBITDA or its related term are showing as below:
NSE:ARISTO's Debt-to-EBITDA is not ranked *
in the Agriculture industry.
Industry Median: 2.16 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Aristo Bio-Tech and Lifescience Debt-to-EBITDA Related Terms
Aristo Bio-Tech and Lifescience Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aristo Bio-Tech and Lifescience Debt-to-EBITDA Chart
For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aristo Bio-Tech and Lifescience Debt-to-EBITDA vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aristo Bio-Tech and Lifescience's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2025) EBITDA data.
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a Debt-to-EBITDA of 6.45 as of Mar. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aristo Bio-Tech and Lifescience.
Is Aristo Bio-Tech and Lifescience's Debt-to-EBITDA too high?
Aristo Bio-Tech and Lifescience's current Debt-to-EBITDA is 6.45. The Agriculture industry median Debt-to-EBITDA is 2.16. Aristo Bio-Tech and Lifescience's value of 6.45 is 198.6% above this industry median. Overall, Aristo Bio-Tech and Lifescience has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Aristo Bio-Tech and Lifescience's Debt-to-EBITDA compare to CTVA and CF?
Aristo Bio-Tech and Lifescience's Debt-to-EBITDA of 6.45 can be compared against companies in the Agriculture industry. The industry median Debt-to-EBITDA is 2.16. Aristo Bio-Tech and Lifescience's value of 6.45 is 198.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for an Agriculture company?
The median Debt-to-EBITDA among Agriculture companies is 2.16, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aristo Bio-Tech and Lifescience's current Debt-to-EBITDA of 6.45 is 198.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Aristo Bio-Tech and Lifescience. For the Agriculture industry, the median Debt-to-EBITDA is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aristo Bio-Tech and Lifescience's current Debt-to-EBITDA is 6.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aristo Bio-Tech and Lifescience stock overvalued right now?
Aristo Bio-Tech and Lifescience (NSE:ARISTO) has a current Debt-to-EBITDA of 6.45. The current Debt-to-EBITDA is 6.45 and 198.6% above the Agriculture industry median of 2.16. Aristo Bio-Tech and Lifescience's overall GF Score™ is 59/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Aristo Bio-Tech and Lifescience (NSE:ARISTO), the current Debt-to-EBITDA is 6.45 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.
59GF Score
Get the complete analysis for NSE:ARISTO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ARISTO has been successfully added to your 
